Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03262779 | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | completed | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT03982459 | National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC | completed | N/A | 76 | University of California, San FranciscoOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT05146219 | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | completed | Phase 2 | 29 | TYK Medicines, IncINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT06747026 | Real-World Immuno-Radiotherapy for Advanced NSCLC(OCEANUS) | completed | — | 338 | Fengming KongOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01463423 | Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) | completed | N/A | 256 | Stanford UniversityOTHER | 3 | Dec 19, 2024 | clinicaltrials |
| NCT06737367 | Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors(Stage I NSCLC) | completed | — | 800 | Jinling Hospital, ChinaOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT01789099 | A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.(UV1-hTERT2012L) | completed | Phase 1 / Phase 2 | 18 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT02754882 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 763 | Samsung Bioepis Co., Ltd.INDUSTRY | 13 | Dec 16, 2024 | clinicaltrials |
| NCT03518554 | A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05462795 | Liquid Biopsy for Early Non-small Lung Cancer Detection | completed | — | 171 | University of ArizonaOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735781 | Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France | completed | — | 101 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05926180 | Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) | completed | Phase 1 | 25 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT00478699 | Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)(GECP-SCAT) | completed | Phase 3 | 500 | Spanish Lung Cancer GroupOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04946019 | MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT02175017 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 104 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03846310 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer(ARC-4) | completed | Phase 1 | 77 | Arcus Biosciences, Inc.INDUSTRY | 4 | Dec 9, 2024 | clinicaltrials |
| NCT06557967 | Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment | completed | — | 22,517 | Daiichi SankyoINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04238130 | Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection(EVOLUTION) | completed | — | 132 | Sun Yat-sen UniversityOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03995875 | Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC(AYAME) | completed | — | 529 | AstraZenecaINDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04691388 | A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor | completed | Phase 2 | 29 | Zhejiang Cancer HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03081689 | Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients | completed | Phase 2 | 46 | Spanish Lung Cancer GroupOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04629300 | Supportive Care Mobile Application for Patients With NSCLC | completed | N/A | 120 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02135679 | The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy | completed | — | 204 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02613507 | Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer(CheckMate 078) | completed | Phase 3 | 504 | Bristol-Myers SquibbINDUSTRY | 4 | Nov 19, 2024 | clinicaltrials |
| NCT02113813 | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 1 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05807893 | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases(SUPER BRAIN) | completed | Phase 2 / Phase 3 | 40 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02488850 | Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC(HAMLET) | completed | N/A | 32 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05898763 | TEIPP Immunotherapy in Patients With NSCLC(TEIPP) | completed | Phase 1 / Phase 2 | 26 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02094261 | Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours(AURA2) | completed | Phase 2 | 210 | AstraZenecaINDUSTRY | 8 | Nov 6, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT04702607 | Functional Lung Imaging With DECT and 4DCT | completed | — | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05347797 | Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit | completed | N/A | 495 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05348187 | Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit | completed | N/A | 309 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05360225 | Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit | completed | — | 5,000 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05304793 | Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer | completed | N/A | 46 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03594747 | A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer | completed | Phase 3 | 360 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT01725165 | Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 85 | M.D. Anderson Cancer CenterOTHER | 2 | Oct 24, 2024 | clinicaltrials |
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | completed | Phase 1 / Phase 2 | 72 | Cancer Research UKOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT03217071 | Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | completed | Phase 2 | 12 | Sue YomOTHER | 1 | Oct 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2025source: clinicaltrials